Will Japan and Europe Switch Activity Impact the U.S. Market?

Embracing Rx-to-OTC Switch: Japan and Europe foster access to nonprescription medications, but will that have an impact on the United States market?

Recently, in Europe and Japan there have been increased Rx-to-OTC switch approvals and an environment fostering switch. The OTC men’s health category is growing in Europe, with the switch approval of Recordati’s Fortacin (lidocaine 7.5mg/prilocaine 2.5 mg) spray for premature ejaculation, via the centralized switch procedure through the European Medicines Agency. This drug marks the fifth medicine approved for switch through this centralized regulatory body, and it is expected to be launched throughout the EU on a nonprescription basis by early 2021. 

Continue reading

Many questions about CBD use for health and wellness – Kline report provides insights on consumers’ perceptions of CBD

There is much hype surrounding consumer-use cannabidiol (CBD) for health and wellness. There are hundreds of companies marketing tons of products; however, there is little consumer education or advertising, along with very nebulous claims, if any, about what the products will do for those who take them. There is even less information on dosage recommendations or clear labeling to help consumers understand how much CBD is actually contained in oral drops, tinctures, gummies, and other popular forms. In short, there’s lot of buzz surrounding this ingredient but little substance.Continue reading